Treatment Of Oropharyngeal Candidiasis By Oravig (Miconazole) Buccal Tablets

Treatment Of Oropharyngeal Candidiasis By Oravig (Miconazole) Buccal Tablets.


Strativa Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Oravig (miconazole) buccal tablets for the care of oropharyngeal candidiasis (OPC), more commonly known as thrush, in adults and children ripen 16 and older Celecoxib. Oravig is the beginning and only local, vocal medication formulation of miconazole - an antifungal medication - approved for this use in the US.



Oravig, which adheres to the gum, utilizes innovative buccal plate technology enabling once-daily dosing that delivers miconazole precisely at the county locale of infection throughout the era with least systemic absorption Buenos herbal site. Oravig is easy-to-use and provides patients with a flavorless, odorless and ready therapy recourse that does not put with continuously activities such as eating and drinking.



Oravig will be offered in a 50 mg dosage ability and is expected to be at one's fingertips in retail pharmacies in the third place of 2010. "The FDA concurrence of Oravig underscores Strativa's commitment to improving patients' overall healing judgement by bringing to market new products that fulfill case needs," said John A MacPhee, President, Strativa Pharmaceuticals. "Oravig offers patients distress from thrush a proven operational remedying in a discreet and handy once-daily formulation".



The FDA approval was based on two central Phase III clinical trials. The in the first place study demonstrated that Oravig utterly resolved signs and symptoms of OPC at rates nearly the same to Mycelex Troche (clotrimazole) administered five times per broad daylight in HIV-positive patients. This randomized, double-blind, double-dummy conditional was conducted in 577 HIV-positive patients in 28 sites in the United States, Canada, and South Africa. A second-best randomized, open-label, multicenter comparative pest conducted in 282 patients who underwent radiotherapy for origin and neck cancer showed that Oravig is protected and efficient in this indefatigable residents who often has reduced salivary flow.